Increasing Incidence, New Treatment Guidelines & Increased R&D to Drive the Global Sepsis Therapeutics Market

The global market for Sepsis Therapeutics is projected to reach US$293.2 million by 2024, driven by growing aging population, increasing disease incidence, and new treatment protocols.  Increased R&D efforts are also expected to drive the global market.

  

Sepsis has become a focal area in the medical community. It is currently regarded a medical emergency, on par with stroke and myocardial infarction. The global market for sepsis therapeutics is driven by increasing incidence of sepsis and growing geriatric population. Further, the increasing number of surgeries and hospital-acquired infections, and increasing research and clinical trials in this area support growth of the market. Current treatment options for treating sepsis are mostly confined to antimicrobials, including anti-bacterials, anti-fungals, anti-virals; and vasopressors, such as Norepinephrine, epinephrine, phenylephrine, vasopressin, and dopamine; and adjunctive therapy. Further, the market growth is supported by increasing awareness of the condition, and a significant number of non-specific therapeutic drugs that are in various stages of clinical trials.

The US FDA approval of Giapreza (angiotensin II) injection from La Jolla Pharmaceutical Company represent the first and only approved synthetic human angiotensin II for treating low blood pressure in adults suffering from septic or other distributive shock. Sales of the drug are currently on the rise, with the forecast for the drug very optimistic. However, despite the obvious need for dedicated sepsis therapeutics, barring GIAPREZA, there are no drugs approved to specifically treat the condition. The high unmet market need therefore offers significant potential for sepsis therapeutics players and potential market entrants.  Future growth of the market is expected to be dominated by novel, first-in-class candidates such as ART-123 (by Asahi Kasei Pharma America), which is presently undergoing Phase 3 trial for the treatment of severe sepsis patients with coagulopathy.

As stated by the new market research report on Sepsis Therapeutics, the United States represents the major leading market for branded sepsis therapeutics, due to high incidence of sepsis in the region, availability of latest and sophisticated devices, high cost of associated drugs, early disease diagnosis, favorable reimbursement policies, easy accessibility to therapeutics, increasing R&D investments, established healthcare infrastructure and rising awareness among patients about the complications related to sepsis. Europe is the second leading market, owing to the high prevalence of the condition and increasing research activities. The Asia-Pacific market is registering fast-paced growth, due to the expansion of the healthcare market, rising presence of leading players, surging prevalence rate, and governmental efforts for the development of treatment options.

Major players in the market include Adrenomed AG, AM-Pharma B.V., Aridis Pharmaceuticals Inc., Asahi Kasei Pharma America, Astellas Pharma Inc., Chong Kun Dang BiO Corporation, Endacea Inc., InflaRx GmbH, La Jolla Pharmaceutical Company, Opsonix, Inc., T2 Biosystems Inc., and TaiRx Inc., among others.

The research report titled "Sepsis Therapeutics - Market Analysis, Trends, and Forecasts" announced by Global Industry Analysts Inc., provides a comprehensive review of market trends, growth drivers, mergers and acquisitions, and other strategic industry activities of major companies worldwide. The report provides market estimates and projections for geographic markets of the US and Rest of World.  

Global Industry Analysts, Inc. 6150 Hellyer Ave., San Jose CA 95138, USA, All Rights Reserved.

For enquiries e-mail us at rsd@strategyr.com or info411@strategyr.com.

For cutting edge analyst reviews on top industries, follow us on Twitter and connect with us on LinkedIna